The Cancer Treatment and Wellness Center at Northern Westchester Hospital and Mount Kisco Medical Group are now enrolling patients for a phase three clinical research study investigating the use of a drug called palbociclib for advanced-stage breast cancer.
“We are very excited to be one of the first sites to participate in this study and one of only three  sites currently enrolling patients in the New York tristate region,” said Dr. Jonathan Goldberg, medical oncologist at Mount Kisco Medical Group and medical director of cancer clinical trials at Northern Westchester Hospital. “Through the clinical trials program at NWH, we are able to provide patients with leading-edge care and access to investigational cancer drugs without having to travel outside of our community.”
The first two phases of human testing focus on verifying a drug’s safety and effectiveness, according to the U.S. Food and Drug Administration. Phase three trials further those efforts by expanding the number of patients involved.
Founded in 1946, Mount Kisco Medical Group has more than 280 physicians representing 40 medical specialties with major campuses in Mount Kisco, Carmel, Katonah, Fishkill and Poughkeepsie. The group is an independent clinical affiliate of Massachusetts General Hospital. Northern Westchester Hospital has more than 700 physicians practicing out of its Mount Kisco facility.
